Crossmark

Improving the prediction of patient survival with the aid of residual convolutional neural network (ResNet) in colorectal cancer with unresectable liver metastases treated with bevacizumab-based chemotherapy

Crossref DOI link: https://doi.org/10.1186/s40644-024-00809-1

Published Online: 2024-12-18

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chiu, Sung-Hua

Li, Hsiao-Chi

Chang, Wei-Chou

Wu, Chao-Cheng

Lin, Hsuan-Hwai

Lo, Cheng-Hsiang

Chang, Ping-Ying
Funding

Funding for this research was provided by:

National Science and Technology Council (NSC 109-2314-B-016-012)

Tri-Service General Hospital (TSGH-D-112068)
License Information

Text and Data Mining valid from 2024-12-18

Version of Record valid from 2024-12-18
More Information

Article History

Received: 13 March 2024

Accepted: 25 November 2024

First Online: 18 December 2024

Declarations

:

: This study was approved by the Ethical Committee of Institutional Review Board (IRB) and a waiver of informed consent was granted for the chart and image review. IRB Protocol number: TSGHIRB No. 2-108-05-153. IRB Protocol title: Development of artificial intelligence approaches for Detection and Characterization of Hepatic Lesion and Evaluation of HCC treatment.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below